By
Medecins Sans Frontieres,
Partners In Health,
Treatment Action Group
Published: Aug. 1, 2023, 8:02 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Access,
Advocacy
Advocates call for clarity on the terms of the Johnson & Johnson's deal with the Stop TB Partnership’s Global Drug Facility to supply generic bedaquiline.
Read More →
By
Treatment Action Group
Published: July 31, 2023, 9:54 p.m.·
Tags:
Scientific research,
Advocacy
A toolkit, developed by Treatment Action Group, is designed to facilitate community participation in the development and review of clinical trials protocols.
Read More →
By
RESULTS UK
Published: July 28, 2023, 8:05 p.m.·
Tags:
Global TB response,
Advocacy
A report, released by RESULTS UK, makes the case for accountability within the global TB response, highlighting the lack of progress against the 2018 global commitments and the role of accountability within these commitments.
Read More →
By
Shaun Palmer et al.
Published: July 19, 2023, 8:14 p.m.·
Tags:
Vaccines,
Research and development
A policy brief outlines recommendations for G20 members to act together to accelerate TB vaccine development.
Read More →
By
TB Vax ARM
Published: July 19, 2023, 6:54 p.m.·
Tags:
Vaccines,
Research and development
A one-pager, developed by TB Vax ARM, provides relevant background information on the critical need for Member States to substantially increase adequate, predictable, and sustainable financing for TB vaccine research.
Read More →
By
Stop TB Partnership
Published: July 13, 2023, 8:25 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Access,
Advocacy
Global Drug Facility announces an agreement with Johnson & Johnson for access to affordable generic versions of bedaquiline; Treatment Action Group, Médecins Sans Frontières and Partners in Health release statements in response to the agreement.
Read More →
By
TB advocates
Published: July 11, 2023, 8:11 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Access,
Advocacy
Advocates demand that Johnson & Johnson commit to non-enforcement of secondary patent on bedaquiline so that access to generic, quality-assured bedaquiline is guaranteed after the primary patent expires on 18 July 2023.
Read More →
By
International Union Against Tuberculosis and Lung Disease
Published: July 6, 2023, 8:06 p.m.·
Tags:
Advocacy
100 sponsored registrations will be offered to civil society members, individuals involved in efforts to address lung health, and survivors of TB. Deadline for application: 25 July 2023
Read More →
By
WHO/Europe
Published: July 4, 2023, 11:38 p.m.·
Tags:
TB care
A guide for affected community and civil society organizations, national TB programs and policy-makers in eastern Europe and central Asia
Read More →
By
Stop TB Partnership
Published: June 29, 2023, 3:51 p.m.·
Tags:
Global TB response,
Advocacy
The Stop TB Partnership launches the Challenge Facility for Civil Society Round 12 with USD 13.5 million in funding for civil society and communities from high TB burden countries.
Read More →
Page 10 of 133 · Total posts: 10
←First
9
10
11
Last→